Canada in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

Product Code GMD07385
Publication Date April 2009
Publisher Global Markets Direct
Product Type Report
Pages 146
ISBN Number not applicable
Change currency
PDF £1,580.00 €1,903 $2,498 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Canada in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

This report is an essential source for in-depth information and data relating to the Canada In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in Canada

Scope

  • The report provides in vitro diagnostics information broken down into detailed categories and segments in Canada.
  • Total revenues, end users
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the in vitro diagnostics devices market in Canada.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets Covered in This Report
    • 3.1 In Vitro Diagnostics
    • 3.2 Clinical Chemistry Test Reagents
      • 3.2.1 Laboratory Reagents
      • 3.2.2 Clinical Chemistry Calibrators and Controls
      • 3.2.3 Clinical Chemistry Rapid Tests
    • 3.3 Immunochemistry Test Reagents
      • 3.3.1 Disease Specific Markers
        • 3.3.1.1 Tumor Markers
        • 3.3.1.2 Cardiac Markers
      • 3.3.2 Disease Specific Test Reagents
        • 3.3.2.1 Auto-Immune Disease
        • 3.3.2.2 Rheumatoid Disease
        • 3.3.2.3 Anemia/ Vitamins
        • 3.3.2.4 Allergy
      • 3.3.3 Drug Related Testing Reagents
        • 3.3.3.1 Therapeutic Drugs
        • 3.3.3.2 Drug of Abuse and Toxicology
      • 3.3.4 Hormone Related Testing Reagents
        • 3.3.4.1 Specific Proteins
        • 3.3.4.2 Fertility and Pregnancy
        • 3.3.4.3 Individual/Specified hormones
        • 3.3.4.4 Specific Organ Function
      • 3.3.5 Immunochemistry Calibrators and Controls
      • 3.3.6 Immunochemistry Rapid Tests
    • 3.4 Blood Test Reagents
      • 3.4.1 Hematology Test Reagents
        • 3.4.1.1 Hematology
        • 3.4.1.2 Immunohaematology
        • 3.4.1.3 Hematology Calibrators and Controls
        • 3.4.1.4 Immunohaematology Controls
      • 3.4.2 Hemostasis Test Reagents
        • 3.4.2.1 Hemostasis
        • 3.4.2.2 Hemostasis Calibrators and Controls
        • 3.4.2.3 Hemostasis Rapid Tests
      • 3.4.3 Tissue Typing Reagents
      • 3.4.4 Monoclonal Antibodies
      • 3.4.5 Cytokines and Immunomodulators
      • 3.4.6 Histology and Cytology Reagents
    • 3.5 Microbiology Test Reagents
      • 3.5.1 Bacteriology Test Reagents
        • 3.5.1.1 Bacteriology Culture
        • 3.5.1.2 Blood Culture
        • 3.5.1.3 Bacteriology Identification and Susceptibility
      • 3.5.2 Microbiology Calibrators and Controls
      • 3.5.3 Microbiology Rapid Tests
    • 3.6 Infectious Immunology Test Reagents
      • 3.6.1 Bacteriology
      • 3.6.2 Virology
        • 3.6.2.1 Hepatitis Viruses
        • 3.6.2.2 Retroviruses
      • 3.6.3 Parasitology
      • 3.6.4 Infectious Immunology Calibrators and Controls
      • 3.6.5 Infectious Immunology Rapid Tests
    • 3.7 Genetic Test Reagents
    • 3.8 Self Testing
    • 3.9 Instruments
  • 4 Healthcare Sector Review
    • 4.1 Healthcare Expenditure
    • 4.2 Healthcare Infrastructure
    • 4.3 Healthcare Policy
    • 4.4 Canada Healthcare Trade Statistics
  • 5 Regulation System
    • 5.1 Medical Equipment Approval Process
      • 5.1.1 Classification
      • 5.1.2 Conformity Assessment
        • 5.1.2.1 Class II
        • 5.1.2.2 Class III
        • 5.1.2.3 Class IV
      • 5.1.3 License Fee
      • 5.1.4 License Application Processing Duration
    • 5.2 Labeling and Packaging
    • 5.3 Post-Market Surveillance
  • 6 Pricing and Reimbursement
  • 7 Distribution Structure
    • 7.1 Distribution Structure
  • 8 In Vitro Diagnostics In Canada
    • 8.1 In Vitro Diagnostics, Canada, Overall Revenue ($ mn), 2000-2015
    • 8.2 In Vitro Diagnostics, Canada, Company Share (2006-2007)
  • 9 Blood Test Reagents In Canada
    • 9.1 Blood Test Reagents Overall Revenue (2000-2015)
      • 9.1.1 Haematology Test Reagents Revenue (2000-2015)
      • 9.1.2 Hemostasis Test Reagents Revenue (2000-2015)
    • 9.2 Blood Test Reagents Distribution Share (2007-2008)
    • 9.3 Blood Test Reagents, Canada, Company Share (2006-2007)
  • 10 Clinical Chemistry Test Reagents In Canada
    • 10.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2015)
    • 10.2 Clinical Chemistry Test Reagents Distribution Share (2007-2008)
    • 10.3 Clinical Chemistry Test Reagents, Canada, Company Share (2006-2007)
  • 11 Genetic Test Reagents In Canada
    • 11.1 Genetic Test Reagents Overall Revenue (2000-2015)
    • 11.2 Genetic Test Reagents Distribution Share (2007-2008)
    • 11.3 Genetic Test Reagents, Canada, Company Share (2006-2007)
  • 12 Immunochemistry Test Reagents In Canada
    • 12.1 Immunochemistry Test Reagents Overall Revenue (2000-2015)
      • 12.1.1 Disease Specific Markers Revenue (2000-2015)
      • 12.1.2 Disease Specific Test Reagents Revenue (2000-2015)
      • 12.1.3 Drug Related Testing Reagents Revenue (2000-2015)
    • 12.2 Immunochemistry Test Reagents Distribution Share (2007-2008)
    • 12.3 Immunochemistry Test Reagents, Canada, Company Share (2006-2007)
  • 13 Infectious Immunology Test Reagents In Canada
    • 13.1 Infectious Immunology Test Reagents Overall Revenue (2000-2015)
      • 13.1.1 Virology Revenue (2000-2015)
    • 13.2 Infectious Immunology Test Reagents Distribution Share (2007-2008)
    • 13.3 Infectious Immunology Test Reagents, Canada, Company Share (2006-2007)
  • 14 Instruments In Canada
    • 14.1 Instruments Overall Revenue (2000-2015)
    • 14.2 Instruments Distribution Share (2007-2008)
  • 15 Microbiology Test Reagents In Canada
    • 15.1 Microbiology Test Reagents Overall Revenue (2000-2015)
      • 15.1.1 Bacteriology Test Reagents Revenue (2000-2015)
    • 15.2 Microbiology Test Reagents Distribution Share (2007-2008)
  • 16 Self Testing In Canada
    • 16.1 Self Testing Overall Revenue (2000-2015)
    • 16.2 Self Testing Distribution Share (2007-2008)
    • 16.3 Self Testing, Canada, Company Share (2006-2007)
  • 17 Overview of Key Companies in Canada In Vitro Diagnostics Market
    • 17.1 F. Hoffmann-La Roche Ltd. Company Profile
      • 17.1.1 Company Overview
      • 17.1.2 Value Chain Analysis
        • 17.1.2.1 Manufacturing
        • 17.1.2.2 Product Development
    • 17.2 Abbott Laboratories Company Profile
      • 17.2.1 Company Overview
      • 17.2.2 Value Chain Analysis
        • 17.2.2.1 Manufacturing
        • 17.2.2.2 Product Development
        • 17.2.2.3 Sales and Marketing
    • 17.3 Beckman Coulter, Inc. Company Profile
      • 17.3.1 Company Overview
      • 17.3.2 Value Chain Analysis
        • 17.3.2.1 Manufacturing
        • 17.3.2.2 Product Development
        • 17.3.2.3 Sales and Marketing
      • 17.3.3 Beckman Coulter, Inc. Pipeline Products
        • 17.3.3.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type
        • 17.3.3.2 Beckman Coulter, Inc. Pipeline Products By Development Stage
        • 17.3.3.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area
        • 17.3.3.4 Beckman Coulter, Inc. Pipeline Products By News Summary
    • 17.4 Dade Behring Holdings, Inc. Company Profile
      • 17.4.1 Company Overview
    • 17.5 Siemens Healthcare Company Profile
      • 17.5.1 Company Overview
      • 17.5.2 Value Chain Analysis
        • 17.5.2.1 Manufacturing
        • 17.5.2.2 Product Development
        • 17.5.2.3 Sales and Marketing
    • 17.6 bioMerieux S.A. Company Profile
      • 17.6.1 Company Overview
      • 17.6.2 Value Chain Analysis
        • 17.6.2.1 Manufacturing
        • 17.6.2.2 Product Development
        • 17.6.2.3 Sales and Marketing
    • 17.7 Ventana Medical Systems, Inc. Company Profile
      • 17.7.1 Company Overview
    • 17.8 Ortho-Clinical Diagnostics Inc. Company Profile
      • 17.8.1 Company Overview
      • 17.8.2 Ortho-Clinical Diagnostics Inc. Pipeline Products
        • 17.8.2.1 Ortho-Clinical Diagnostics Inc. Pipeline Products By Equipment Type
        • 17.8.2.2 Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
        • 17.8.2.3 Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
        • 17.8.2.4 Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary
    • 17.9 Mindray Medical International Limited Company Profile
      • 17.9.1 Company Overview
    • 17.10 Gen-Probe Incorporated Company Profile
      • 17.10.1 Company Overview
      • 17.10.2 Value Chain Analysis
        • 17.10.2.1 Manufacturing
        • 17.10.2.2 Product Development
        • 17.10.2.3 Sales and Marketing
      • 17.10.3 Gen-Probe Incorporated Pipeline Products
        • 17.10.3.1 Gen-Probe Incorporated Pipeline Products By Equipment Type
        • 17.10.3.2 Gen-Probe Incorporated Pipeline Products By Development Stage
        • 17.10.3.3 Gen-Probe Incorporated Pipeline Products By Therapy Area
        • 17.10.3.4 Gen-Probe Incorporated Pipeline Products By Clinical Trials
        • 17.10.3.5 Gen-Probe Incorporated Pipeline Products By News Summary
    • 17.11 Digene Corporation Company Profile
      • 17.11.1 Company Overview
  • 18 Financial Deals Landscape
    • 18.1 Merger
      • 18.1.1 Pacgen Biopharmaceuticals Terminates Merger Agreement with Medigen Biotechnology
    • 18.2 Acquisition
      • 18.2.1 Cytognomix Receives Investment from Ontario Genomics Institute
      • 18.2.2 JAG Media Holdings to Acquire CardioGenics from Yahia Gawad
      • 18.2.3 Amorfix Life Sciences Receives Investment from Biogen Idec
    • 18.3 Partnerships
      • 18.3.1 The Medcan Clinic Enters into an Agreement with PGXL laboratories
      • 18.3.2 Newfound Genomics Enters Into An Agreement With Genesis Group
      • 18.3.3 Assay Designs Signs An Agreement With Abnova
      • 18.3.4 Miraculins Signs A Licensing Agreement With Mount Sinai Hospital
      • 18.3.5 Warnex Signs An Agreement With GENDIA
      • 18.3.6 Exiqon And Roche Diagnostics Enter Into Partnership
  • 19 Recent Developments
    • 19.1 Product News
      • 19.1.1 Mar 11, 2009: Cepheid's Xpert MRSA/SA Blood Culture (BC) Test Receives Health Canada License
      • 19.1.2 Mar 10, 2009: ArcticDx Inc. Launches Macula Risk Genetic Test For Age-Related Macular Degeneration
      • 19.1.3 Jan 22, 2009: Miraculins Announces Successful Completion Of Testing Of P2V Immunoassay
      • 19.1.4 Jan 13, 2009: Invitrogen Announces Health Canada Approval For DynaChip HLA Antibody Analysis System
      • 19.1.5 Dec 18, 2008: Evaluation Of WavSTAT During Colonoscopies
      • 19.1.6 Nov 13, 2008: Perceptronix to Exhibit at Toronto Academy of Dentistry Annual Winter Clinic
      • 19.1.7 Nov 10, 2008: LungSign Study To Monitor Lung Cancer Recurrence
      • 19.1.8 Oct 08, 2008: Luminex Corporation Receives Clearance From Health Canada For xTAG Respiratory Viral Panel
  • 20 Appendix
    • 20.1 Global Markets Direct Research Methodology
    • 20.2 Coverage
    • 20.3 Secondary Research
    • 20.4 Primary Research
    • 20.5 Models
    • 20.6 Forecasts
    • 20.7 Expert Panel Validation
    • 20.8 Currency Conversion
    • 20.9 Contact Us
    • 20.10 Disclaimer
  • 1 List of Tables
    • Table 1: Number of Physicians by Province in Canada, 2001 and 2005
    • Table 2: Hospital Wards by Specialty in Canada, 2003-2007
    • Table 3: Doctors by Specialty in Canada, 2003-2007
    • Table 4: Canada Healthcare Trade Statistics, 2001-2006
    • Table 5: Medical Equipment Classification in Canada, 2007
    • Table 6: Medical Equipment Licensing Fee in Canada, 2007
    • Table 7: Medical Equipment License Processing Duration in Canada, 2007
    • Table 8: In Vitro Diagnostics, Canada, Overall Revenue ($ mn), 2000-2015
    • Table 9: In Vitro Diagnostics, Canada, Cross-Category Analysis, 2000-2015
    • Table 10: In Vitro Diagnostics, Canada, Overall Revenue ($ mn), Historic, 2000-2008
    • Table 11: In Vitro Diagnostics, Canada, Overall Revenue ($ mn), Forecast, 2008-2015
    • Table 12: In Vitro Diagnostics, Canada, Company Share by Revenue ($ mn), 2006-2007
    • Table 13: Blood Test Reagents, Canada, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 14: Blood Test Reagents, Canada, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 15: Haematology Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 16: Haematology Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 17: Hemostasis Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 18: Hemostasis Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 19: Blood Test Reagents, Canada, Distribution Share by Revenue ($mn), 2007-2008
    • Table 20: Blood Test Reagents, Canada, Company Share by Revenue ($ mn), 2006-2007
    • Table 21: Clinical Chemistry Test Reagents, Canada, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 22: Clinical Chemistry Test Reagents, Canada, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 23: Clinical Chemistry Test Reagents, Canada, Distribution Share by Revenue ($mn), 2007-2008
    • Table 24: Clinical Chemistry Test Reagents, Canada, Company Share by Revenue ($ mn), 2006-2007
    • Table 25: Genetic Test Reagents, Canada, Revenue ($ mn), Historic, 2000-2008
    • Table 26: Genetic Test Reagents, Canada, Revenue ($ mn), Forecast, 2008-2015
    • Table 27: Genetic Test Reagents, Canada, Distribution Share by Revenue ($mn), 2007-2008
    • Table 28: Genetic Test Reagents, Canada, Company Share by Revenue ($ mn), 2006-2007
    • Table 29: Immunochemistry Test Reagents, Canada, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 30: Immunochemistry Test Reagents, Canada, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 31: Disease Specific Markers, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 32: Disease Specific Markers, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 33: Disease Specific Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 34: Disease Specific Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 35: Drug Related Testing Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 36: Drug Related Testing Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 37: Hormone Related Testing Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 38: Hormone Related Testing Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 39: Immunochemistry Test Reagents, Canada, Distribution Share by Revenue ($mn), 2007-2008
    • Table 40: Immunochemistry Test Reagents, Canada, Company Share by Revenue ($ mn), 2006-2007
    • Table 41: Infectious Immunology Test Reagents, Canada, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 42: Infectious Immunology Test Reagents, Canada, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 43: Virology, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 44: Virology, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 45: Infectious Immunology Test Reagents, Canada, Distribution Share by Revenue ($mn), 2007-2008
    • Table 46: Infectious Immunology Test Reagents, Canada, Company Share by Revenue ($ mn), 2006-2007
    • Table 47: Instruments, Canada, Revenue ($ mn), Historic, 2000-2008
    • Table 48: Instruments, Canada, Revenue ($ mn), Forecast, 2008-2015
    • Table 49: Instruments, Canada, Distribution Share by Revenue ($mn), 2007-2008
    • Table 50: Microbiology Test Reagents (Bacteriology Test Reagents), Canada, Revenue ($ mn), Historic, 2000-2008
    • Table 51: Microbiology Test Reagents (Bacteriology Test Reagents), Canada, Revenue ($ mn), Forecast, 2008-2015
    • Table 52: Bacteriology Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 53: Bacteriology Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 54: Microbiology Test Reagents, Canada, Distribution Share by Revenue ($mn), 2007-2008
    • Table 55: Self Testing, Canada, Revenue ($ mn), Historic, 2000-2008
    • Table 56: Self Testing, Canada, Revenue ($ mn), Forecast, 2008-2015
    • Table 57: Self Testing, Canada, Distribution Share by Revenue ($mn), 2007-2008
    • Table 58: Self Testing, Canada, Company Share by Revenue ($ mn), 2006-2007
    • Table 59: Beckman Coulter, Inc. Pipeline Products by Equipment Type
    • Table 60: Beckman Coulter, Inc. Pipeline Products By Development Stage
    • Table 61: Beckman Coulter, Inc. Pipeline Products By Therapy Area
    • Table 62: Beckman Coulter, Inc. Pipeline Products By News Summary
    • Table 63: Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type
    • Table 64: Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
    • Table 65: Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
    • Table 66: Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary
    • Table 67: Gen-Probe Incorporated Pipeline Products by Equipment Type
    • Table 68: Gen-Probe Incorporated Pipeline Products By Development Stage
    • Table 69: Gen-Probe Incorporated Pipeline Products By Therapy Area
    • Table 70: Gen-Probe Incorporated Pipeline Products By Clinical Trials
    • Table 71: Gen-Probe Incorporated Pipeline Products By News Summary
    • Table 72: Pacgen Biopharmaceuticals Terminates Merger Agreement With Medigen Biotechnology
    • Table 73: Cytognomix Receives Investment From Ontario Genomics Institute
    • Table 74: JAG Media Holdings To Acquire CardioGenics From Yahia Gawad
    • Table 75: Amorfix Life Sciences Receives Investment From Biogen Idec
    • Table 76: The Medcan Clinic Enters Into An Agreement With PGXL laboratories
    • Table 77: Newfound Genomics Enters Into An Agreement With Genesis Group
    • Table 78: Assay Designs Signs An Agreement With Abnova
    • Table 79: Miraculins Signs A Licensing Agreement With Mount Sinai Hospital
    • Table 80: Warnex Signs An Agreement With GENDIA
    • Table 81: Exiqon And Roche Diagnostics Enter Into Partnership
    • Table 82: USD to Local Currency, Average Exchange Rate 2008
  • 1.2 List of Figures
    • Figure 1: Healthcare Financing in Canada, 2004
    • Figure 2: Healthcare Expenditure in Canada, 2000 - 2006
    • Figure 3: In Vitro Diagnostics, Canada, Overall Revenue ($ mn), 2000-2015
    • Figure 4: In Vitro Diagnostics, Canada, Cross-Category Analysis, 2000-2015
    • Figure 5: In Vitro Diagnostics, Canada, Overall Revenue ($ mn), Historic, 2000-2008
    • Figure 6: In Vitro Diagnostics, Canada, Overall Revenue ($ mn), Forecast, 2008-2015
    • Figure 7: In Vitro Diagnostics, Canada, Company Share (%), 2007
    • Figure 8: Blood Test Reagents, Canada, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 9: Blood Test Reagents, Canada, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 10: Haematology Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 11: Haematology Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 12: Hemostasis Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 13: Hemostasis Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 14: Blood Test Reagents, Canada, Company Share (%), 2007
    • Figure 15: Clinical Chemistry Test Reagents, Canada, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 16: Clinical Chemistry Test Reagents, Canada, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 17: Clinical Chemistry Test Reagents, Canada, Company Share (%), 2007
    • Figure 18: Genetic Test Reagents, Canada, Revenue ($ mn), Historic, 2000-2008
    • Figure 19: Genetic Test Reagents, Canada, Revenue ($ mn), Forecast, 2008-2015
    • Figure 20: Genetic Test Reagents, Canada, Company Share (%), 2007
    • Figure 21: Immunochemistry Test Reagents, Canada, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 22: Immunochemistry Test Reagents, Canada, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 23: Disease Specific Markers, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 24: Disease Specific Markers, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 25: Disease Specific Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 26: Disease Specific Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 27: Drug Related Testing Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 28: Drug Related Testing Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 29: Hormone Related Testing Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 30: Hormone Related Testing Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 31: Immunochemistry Test Reagents, Canada, Company Share (%), 2007
    • Figure 32: Infectious Immunology Test Reagents, Canada, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 33: Infectious Immunology Test Reagents, Canada, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 34: Virology, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 35: Virology, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 36: Infectious Immunology Test Reagents, Canada, Company Share (%), 2007
    • Figure 37: Instruments, Canada, Revenue ($ mn), Historic, 2000-2008
    • Figure 38: Instruments, Canada, Revenue ($ mn), Forecast, 2008-2015
    • Figure 39: Microbiology Test Reagents (Bacteriology Test Reagents), Canada, Revenue ($ mn), Historic, 2000-2008
    • Figure 40: Microbiology Test Reagents (Bacteriology Test Reagents), Canada, Revenue ($ mn), Forecast, 2008-2015
    • Figure 41: Bacteriology Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 42: Bacteriology Test Reagents, Canada, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 43: Self Testing, Canada, Revenue ($ mn), Historic, 2000-2008
    • Figure 44: Self Testing, Canada, Revenue ($ mn), Forecast, 2008-2015
    • Figure 45: Self Testing, Canada, Company Share (%), 2007
    • Figure 46: F. Hoffmann-La Roche Ltd Value Chain Analysis
    • Figure 47: Abbott Laboratories Value Chain Analysis
    • Figure 48: Beckman Coulter, Inc. Value Chain Analysis
    • Figure 49: Siemens Medical Solutions Value Chain Analysis
    • Figure 50: Biomerieux Sa Value Chain Analysis
    • Figure 51: Gen-Probe Incorporated Value Chain Analysis
    • Figure 52: Global Markets Direct Methodology